Efficacy and Effectiveness of an rVSV-Vectored Vaccine Expressing Ebola Surface Glycoprotein: Interim Results from the Guinea Ring Vaccination Cluster-Randomised Trial

Hdl Handle:
http://hdl.handle.net/10144/575218
Title:
Efficacy and Effectiveness of an rVSV-Vectored Vaccine Expressing Ebola Surface Glycoprotein: Interim Results from the Guinea Ring Vaccination Cluster-Randomised Trial
Authors:
Henao-Restrepo, A M; Longini, I M; Egger, M; Dean, N E; Edmunds, W J; Camacho, A; Carroll, M W; Doumbia, M; Draguez, B; Duraffour, S; Enwere, G; Grais, R; Gunther, S; Hossmann, S; Kondé, M K; Kone, S; Kuisma, E; Levine, M M; Mandal, S; Norheim, G; Riveros, X; Soumah, A; Trelle, S; Vicari, A S; Watson, C H; Kéïta, S; Kieny, M P; Røttingen, J-A
Journal:
Lancet
Abstract:
A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola vaccine candidate. We report the results of an interim analysis of a trial of rVSV-ZEBOV in Guinea, west Africa.
Publisher:
Elsevier
Issue Date:
3-Aug-2015
URI:
http://hdl.handle.net/10144/575218
DOI:
10.1016/S0140-6736(15)61117-5
PubMed ID:
26248676
Language:
en
ISSN:
1474-547X
Appears in Collections:
Vaccination

Full metadata record

DC FieldValue Language
dc.contributor.authorHenao-Restrepo, A Men_GB
dc.contributor.authorLongini, I Men_GB
dc.contributor.authorEgger, Men_GB
dc.contributor.authorDean, N Een_GB
dc.contributor.authorEdmunds, W Jen_GB
dc.contributor.authorCamacho, Aen_GB
dc.contributor.authorCarroll, M Wen_GB
dc.contributor.authorDoumbia, Men_GB
dc.contributor.authorDraguez, Ben_GB
dc.contributor.authorDuraffour, Sen_GB
dc.contributor.authorEnwere, Gen_GB
dc.contributor.authorGrais, Ren_GB
dc.contributor.authorGunther, Sen_GB
dc.contributor.authorHossmann, Sen_GB
dc.contributor.authorKondé, M Ken_GB
dc.contributor.authorKone, Sen_GB
dc.contributor.authorKuisma, Een_GB
dc.contributor.authorLevine, M Men_GB
dc.contributor.authorMandal, Sen_GB
dc.contributor.authorNorheim, Gen_GB
dc.contributor.authorRiveros, Xen_GB
dc.contributor.authorSoumah, Aen_GB
dc.contributor.authorTrelle, Sen_GB
dc.contributor.authorVicari, A Sen_GB
dc.contributor.authorWatson, C Hen_GB
dc.contributor.authorKéïta, Sen_GB
dc.contributor.authorKieny, M Pen_GB
dc.contributor.authorRøttingen, J-Aen_GB
dc.date.accessioned2015-08-18T21:20:06Z-
dc.date.available2015-08-18T21:20:06Z-
dc.date.issued2015-08-03-
dc.identifier.citationEfficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. 2015: Lanceten_GB
dc.identifier.issn1474-547X-
dc.identifier.pmid26248676-
dc.identifier.doi10.1016/S0140-6736(15)61117-5-
dc.identifier.urihttp://hdl.handle.net/10144/575218-
dc.description.abstractA recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola vaccine candidate. We report the results of an interim analysis of a trial of rVSV-ZEBOV in Guinea, west Africa.en_GB
dc.languageENG-
dc.language.isoenen
dc.publisherElsevieren_GB
dc.rightsArchived with thanks to Lancet (London, England)en_GB
dc.titleEfficacy and Effectiveness of an rVSV-Vectored Vaccine Expressing Ebola Surface Glycoprotein: Interim Results from the Guinea Ring Vaccination Cluster-Randomised Trialen
dc.identifier.journalLanceten_GB

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.